Mira Pharmaceuticals (MIRA) Long-Term Deferred Tax (2022 - 2025)

Mira Pharmaceuticals has disclosed Long-Term Deferred Tax across 4 years of filings, most recently posting $9.6 million for Q4 2025.

• Long-Term Deferred Tax for Q4 2025 came in at $9.6 million, up 39.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.6 million (up 39.13% YoY), and the FY2025 annual result was $9.6 million, up 39.13% from the prior year.
• Long-Term Deferred Tax came in at $9.6 million for Q4 2025 at Mira Pharmaceuticals, up from $6.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $9.6 million in Q4 2025 to a low of $1291.0 in Q4 2023.
• The 4-year median for Long-Term Deferred Tax is $3.5 million (2022), against an average of $4.1 million.
• Across the five-year window, Long-Term Deferred Tax slumped 98.61% in 2023 and surged 534369.4% in 2024, its largest moves.
• Mira Pharmaceuticals' Long-Term Deferred Tax stood at $92736.0 in 2022, then plunged by 98.61% to $1291.0 in 2023, then soared by 534369.4% to $6.9 million in 2024, then surged by 39.13% to $9.6 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $9.6 million (Q4 2025), $6.9 million (Q4 2024), and $1291.0 (Q4 2023), per Business Quant data.